These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 5511868)

  • 21. [Isolation and characterization of the fibrin stabilizing factor from human thrombocytes].
    Bohn H
    Thromb Diath Haemorrh; 1970 Jun; 23(3):455-68. PubMed ID: 4194158
    [No Abstract]   [Full Text] [Related]  

  • 22. [The significance of changes in the functional properties of blood platelets, factor XIII activity and fibrin clot quality in the pathogenesis of hemorrhagic diathesis secondary to experimental vitamin C deficiency].
    Sushkevich GN; Khnychev SS; Oĭvin VI
    Vopr Pitan; 1969; 28(5):23-7. PubMed ID: 5370913
    [No Abstract]   [Full Text] [Related]  

  • 23. A simple, rapid determination of fibrin degradation product by cross-over immunoelectrophoresis.
    Pongpipat D; Suvatte V; Ratanawong A
    J Med Assoc Thai; 1972 Dec; 55(12):732-5. PubMed ID: 4650734
    [No Abstract]   [Full Text] [Related]  

  • 24. [Studies on fibrinolysis in equivalents of the Sanarelli-Shwartzman phenomenon in obstetrics. Immunochemical demonstration of derivatives of fibrin(ogen)].
    Steichele DF; Herschlein HJ
    Thromb Diath Haemorrh; 1967 Dec; 18(3-4):462-74. PubMed ID: 5590239
    [No Abstract]   [Full Text] [Related]  

  • 25. [Studies on the blood coagulation factor XIII in patients with increased levels of FDP D-dimer].
    Okumura N; Matsuzawa A; Terasawa F; Kameko M; Sasaki Y; Nakagoshi R; Ishikawa S; Hashikura Y; Matsunami H; Kawasaki S
    Rinsho Byori; 1995 Mar; 43(3):269-74. PubMed ID: 7745833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The in vitro effects of fibrinogen concentrate, factor XIII and fresh frozen plasma on impaired clot formation after 60% dilution.
    Haas T; Fries D; Velik-Salchner C; Reif C; Klingler A; Innerhofer P
    Anesth Analg; 2008 May; 106(5):1360-5, table of contents. PubMed ID: 18420845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Diagnostic and therapeutic measures in congenital blood coagulation disorders].
    Eggert JH
    Dtsch Zahnarztl Z; 1982 Nov; 37(11):877-84. PubMed ID: 6816566
    [No Abstract]   [Full Text] [Related]  

  • 28. [Physiopathology of the process of fibrin stabilization].
    Cucuianu M; Vasile V; Popescu TA
    Med Interna (Bucur); 1973 Apr; 25(4):397-412. PubMed ID: 4800023
    [No Abstract]   [Full Text] [Related]  

  • 29. [Behavior of the fibrin-stabilizing blood coagulation factor XIII in hemorrhages after tooth extractions].
    Vogel C
    Dtsch Zahnarztl Z; 1980 Jan; 35(1):137-8. PubMed ID: 6967809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Methodological studies for the determination of protein 8 and of its biological activity].
    Ballerini G; Barbui T; Scagliarini F
    Schweiz Med Wochenschr; 1974 Sep; 104(39):1370-2. PubMed ID: 4213933
    [No Abstract]   [Full Text] [Related]  

  • 31. Fibrin formation by wounded bronchial epithelial cell layers in vitro is essential for normal epithelial repair and independent of plasma proteins.
    Perrio MJ; Ewen D; Trevethick MA; Salmon GP; Shute JK
    Clin Exp Allergy; 2007 Nov; 37(11):1688-700. PubMed ID: 17892513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitation of the coagulation inhibition in vivo due to breakdown products of fibrin.
    Mitchell PS; Beller FK
    Thromb Diath Haemorrh; 1970 Jun; 23(3):477-85. PubMed ID: 4989113
    [No Abstract]   [Full Text] [Related]  

  • 33. Quantitative estimation of fibrin stabilizing factor, alterations of its activity by fibrinolysis.
    Heene DL
    Thromb Diath Haemorrh; 1968 Jul; 19(3):600-1. PubMed ID: 5708137
    [No Abstract]   [Full Text] [Related]  

  • 34. Congenital factor XIII deficiency. Report of 2 cases.
    Fradera J; Haddock J; Pérez-Santiago E; Maldonado N
    Bol Asoc Med P R; 1969 Aug; 61(8):294-9. PubMed ID: 5271545
    [No Abstract]   [Full Text] [Related]  

  • 35. Fibrin sealants in supporting surgical techniques: strength in factor XIII.
    Phillips M; Dickneite G; Metzner H
    Cardiovasc Surg; 2003 Aug; 11 Suppl 1():13-6. PubMed ID: 12869983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Immunological demonstration of fibrinogen-fibrin break-down products in serum and urine. Clinical significance].
    Gormsen J; Clausen NT
    Ugeskr Laeger; 1973 Aug; 135(32):1682-7. PubMed ID: 4589773
    [No Abstract]   [Full Text] [Related]  

  • 37. [Obtaining anti-fibrinogen serum used for determining fibrinogen and fibrin decomposition products].
    Elizarova AI; Fedorova ZD
    Lab Delo; 1971; 12():722-4. PubMed ID: 4111443
    [No Abstract]   [Full Text] [Related]  

  • 38. [A case of fibrin stabilizing factor (FSF) deficiency].
    Amris CJ; Ranek L
    Ugeskr Laeger; 1965 Dec; 127(52):1673-8. PubMed ID: 5868675
    [No Abstract]   [Full Text] [Related]  

  • 39. Estimation of plasma fibrin-stabilizing factor in families showing congenital deficiencies.
    Losowsky MS; Hall R
    Clin Sci; 1966 Feb; 30(1):171-8. PubMed ID: 5910931
    [No Abstract]   [Full Text] [Related]  

  • 40. Humoral antibodies in the host directed against tumor cells after suppression of ascites tumor by heteroimmune sera.
    Rao VS; Sirsi M
    Cancer Res; 1971 Aug; 31(8):1153-8. PubMed ID: 5095980
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.